Knopp, VCs launch Areteia with $350M series A to advance asthma candidate

Newly launched spinout Areteia has drawn a series A round of up to $350 million to advance a repurposed candidate through Phase III testing for eosinophilic asthma, positioning it as an oral alternative to targeted biologics such as IL-5 inhibitors.

Bain Capital Life Sciences led the round for Areteia Therapeutics Inc., created by Knopp Biosciences LLC and Population Health Partners and launched Tuesday...